VBI Vaccines Inc. (VBIV) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to VBI Vaccines Inc. (VBIV) Reports In-Line Q2 EPS

VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022 8:00 AM EDT

PreHevbrio [Hepatitis B Vaccine (Recombinant)] launched in the U.S. at the end of Q1 2022 advancing through commercial stage gates required to enable broad access to the 3-antigen adult hepatitis B (HBV) vaccine FDA Orphan Drug Designation received for VBI-1901 for treatment of glioblastoma (GBM) in June 2022 Two new clinical studies in GBM patients expected to start before the end of 2022 In partnership with the Government of Canada, new clinical study assessing pan-coronavirus vaccine candidate expected to start in Q3 2022 Initial Phase 2 human proof of concept combination study data from VBI-2601 + siRNA in... More